Tags: Recurring

NCT05061550 – A Phase II Open-label, Multicenter, Randomized Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

NCT04239573 – EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

NCT05136196 – S2101 Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) – A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers – an immunoMATCH Pilot Study

NCT05675449 – A Phase 1B, Open-label Study of Elranatamab in Combination with Carfilzomib Plus Dexamethasone and Elranatamab in Combination with PF-07901801 in Participants with Relapsed Refractory Multiple Myeloma

NCT06157151 – A Randomized, Open Label, Two-Arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab Monotherapy in Patients with Recurrent or Metastatic Cervical Cancer

NCT06253130 – A First-In-Human, Phase 1/2, Open-Label, Multi-Center, Dose-Escalation, Dose-Optimization, and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy and in Combination in Participants with Advanced Solid Tumors

NCT00969111 – GU010-18 Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy

NCT06203600 – S2303, Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel +Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS = 1Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

NCT05548296 – A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status

NCT05346835 – Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma

1
2
3
Next